Therefore, VEGF/VEGFR inhibitors can inhibit the recruitment of immunosuppressive cells to the tumor microenvironment, restore the function and phenotype of APCs, and promote infiltration of Teff cells, which supports the synergistic effect of immunotherapy and anti-angiogenic therapy. This evidence concerns the gene VEGFA and neoplasm.